Legal & General Group
CKPT

Legal & General Group’s Checkpoint Therapeutics CKPT Stock Holding History

Legal & General Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-633
Closed -$20K – 3518
2021
Q1 		$20K Sell
633
-4,425
-87% -$148K ﹤0.01% 3128
2020
Q4 		$134K Buy
5,058
+4,540
+876% +$115K ﹤0.01% 2504
2020
Q3 		$14K Sell
518
-195
-27% -$4.68K ﹤0.01% 3095
2020
Q2 		$14K Buy
713
+217
+44% +$3.95K ﹤0.01% 3211
2020
Q1 		$7K Hold
496
– – ﹤0.01% 3218
2019
Q4 		$9K Buy
496
+110
+28% +$1.84K ﹤0.01% 3304
2019
Q3 		$10K Hold
386
– – ﹤0.01% 3265
2019
Q2 		$13K Buy
+386
New +$15.1K ﹤0.01% 3307

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Legal & General Group's CKPT Position: Q2 2021 in Review

Legal & General Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 633 shares — an estimated $20K sold.

Legal & General Group first reported a position in CKPT in Q2 2019 and held it in 8 quarters. The position peaked at $134K in Q4 2020. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

  • Legal & General Group reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 633 Checkpoint Therapeutics shares in Q2 2021, an estimated $20K.
  • Legal & General Group first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's Checkpoint Therapeutics position peaked at $134K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.